 |
|
|
| |
Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1)
|
| |
| |
Reported by Jules Levin
International HIV and Hepatitis Drug Resistance Workshop, June 8-12, Dubrovnic, Croatia
JM Strizki, PM McNicholas, P Mann, L Wojcik, P Qiu,
J Shen, M McCarthy, LM Dunkle, and TA Black
Merck Research Laboratories
Kenilworth, NJ
|
| |
|
|
|
|
|
